Get the app!
Back to Trades
Total Value
$5.6M
Net $5.6M sold
Filing Date
Jun 26, 2026
9 transactions
Sales
$5.6M
9 transactions

Trade Summary

On Jun 23, 2026 through Jun 25, 2026, Rhodes Jason P, Insider, sold $5.6M of Dyne Therapeutics, Inc. (DYN) across 9 transactions. The filing covers Common Stock and reflects net selling of $5.6M. Reported prices ranged from $21.02 to $21.13. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Company Information

Ticker Symbol
DYN
CIK
0001818794

Insider Information

Role
Insider
Location
WALTHAM, MA

Filing Details

Filing Date
Jun 26, 2026
Transaction Date
Jun 23, 2026
Accession Number
0001577014-26-000010
Form Type
4
Net Trading Amount
-$5.6M

Non-Derivative Transactions

DateSecuritySharesPriceTypeValue
Jun 23, 2026Common Stock77,855$21.13Sale$1.6M
Jun 23, 2026Common Stock39,131$21.13Sale$826.8K
Jun 23, 2026Common Stock30,774$21.13Sale$650.3K
Jun 24, 2026Common Stock50,530$21.02Sale$1.1M
Jun 24, 2026Common Stock25,397$21.02Sale$533.8K
Jun 24, 2026Common Stock19,973$21.02Sale$419.8K
Jun 25, 2026Common Stock12,699$21.10Sale$267.9K
Jun 25, 2026Common Stock6,382$21.10Sale$134.7K
Jun 25, 2026Common Stock5,019$21.10Sale$105.9K

Want live alerts when Rhodes Jason P trades again?

Download Insider Trades to track DYN, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

Footnotes

  1. (F1)Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026.
  2. (F2)The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2), (6) and (7).
  3. (F3)The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any.
  4. (F4)The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any.
  5. (F5)The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.
  6. (F6)The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.13 inclusive.
  7. (F7)The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.255 inclusive.
  8. (F8)The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any.

SEC Filing

View on SEC Daily

View the complete filing document on SEC Daily.